Argos Therapeutics, Inc.
ARGS
ARGS was delisted on the 24th of April, 2018.
1 hedge funds and large institutions have $83K invested in Argos Therapeutics, Inc. in 2018 Q3 according to their latest regulatory filings, with funds opening new positions, 0 increasing their positions, reducing their positions, and 3 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
45% less capital invested
Capital invested by funds: $150K → $83K (-$66.9K)
75% less funds holding
Funds holding: 4 → 1 (-3)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 3
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WS
Wedbush Securities
Los Angeles,
California
|
-$13K |
| 2 |
MAM
Meeder Asset Management
Dublin,
Ohio
|
-$936 |
ARGS Hedge Fund Activity: Q3 2018 in Review
1 of the 4,375 institutional investors tracked by Wall St. Rank reported a position in Argos Therapeutics, Inc. (ARGS) for Q3 2018, worth a combined $83K — down 45% from $150K a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of ARGS and 0 opened new positions — a net loss of 3 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Wedbush Securities, exiting entirely with an estimated $13K sold.
- 1 institutional investor held Argos Therapeutics, Inc. (ARGS) as of Q3 2018, down from 4 in Q2 2018.
- Funds reported $83K of Argos Therapeutics, Inc. stock for Q3 2018, down 45% quarter-over-quarter.
- 0 funds opened new Argos Therapeutics, Inc. positions in Q3 2018 and 3 closed out, a net change of -3 holders.
- The largest Argos Therapeutics, Inc. seller in Q3 2018 was Wedbush Securities, an estimated $13K sold.
Based on aggregated 13F filings for Q3 2018.